Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types among Dutch STI Clinic Visitors

Background. Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population. Methods. We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually transmitted infection clinics. Vaginal swabs were analyzed using a polymerase chain reaction-based assay (SPF10-LiPA25) able to detect the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared hrHPV... Mehr ...

Verfasser: Woestenberg, Petra J
King, Audrey J
van Benthem, Birgit Hb
Donken, Robine
Leussink, Suzan
van der Klis, Fiona R M
de Melker, Hester E.
van der Sande, Marianne A B
Hoebe, Christian J P A
Bogaards, Johannes A
Medical Microbiological Laboratories and the Public Health Services
Dokumenttyp: Artikel
Erscheinungsdatum: 2018
Schlagwörter: Cervarix / human papillomavirus / human papillomavirus vaccine / public health / vaccine effectiveness / Immunology and Allergy / Infectious Diseases
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27456374
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dspace.library.uu.nl/handle/1874/363631